AZD 0284Alternative Names: AZD0284
Latest Information Update: 28 Dec 2016
At a glance
- Originator AstraZeneca
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
Most Recent Events
- 01 Dec 2016 Phase-I clinical trials in Plaque psoriasis (In volunteers) in United Kingdom (PO) (NCT02976831)
- 09 Nov 2016 Preclinical trials in Plaque psoriasis in United Kingdom (PO) before December 2016 (NCT02976831)